Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent's PD-1 Candidate Effective Against NSCLC; Will Start Phase III Trial

publication date: Sep 20, 2018

Innovent Biologics of Suzhou reported that its PD-1 candidate, sintilimab, produced a 68% objective response rate in first-line patients with non-squamous non-small cell lung cancer. Sintilimab was administered in combination with pemetrexed and cisplatin in the Phase I trial. Based on the data, Innovent said it would start a 378-patient Phase III trial of the drug in the same population. China's NMPA has already accepted Innovent's NDA filing for sintilimab under Priority Status rules as a treatment for classical Hodgkin's Lymphoma. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital